Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile.

Wang, Ting; McAuslane, Neil; Goettsch, Wim G; Leufkens, Hubert G M; De Bruin, Marie L

Wang, Ting; McAuslane, Neil; Goettsch, Wim G; Leufkens, Hubert G M; De Bruin, Marie L.

Afiliación

Wang T; Centre for Innovation in Regulatory Science (CIRS), London, United Kingdom.
McAuslane N; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands.
Goettsch WG; Centre for Innovation in Regulatory Science (CIRS), London, United Kingdom.
Leufkens HGM; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands.
De Bruin ML; National Health Care Institute, Diemen, Netherlands.

Front Pharmacol ; 13: 948161, 2022.

Article en En | MEDLINE | ID: mdl-35924050

Palabras clave

company strategies; drug development; evidence generation; health technology assessment (HTA); reimbursement; target product profile (TPP); value proposition

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Health_technology_assessment / Prognostic_studies / Qualitative_research Idioma: En Revista: Front Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google